Drug Trial Radar · NCT04741542
Safety of SP-420 in the Treatment of Transfusional Iron Overload
Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Mar 9, 2021
Primary completion
Jan 10, 2024
Study completion Jan 10, 2024
Sponsor
- Lead sponsor
- The University of Texas Health Science Center at San AntonioAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Abfero Pharmaceuticals, Inc
- First posted
- Feb 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with transfusional iron overload and treats them with the investigational iron chelator, SP-420. SP-420 may be better tolerated and safer than commercially available iron chelators. Iron chelation therapy (ICT) has been shown to improve outcomes in iron overload, but adherence is poor due to problems related to ease of administration, tolerability, and safety.
Conditions
- Iron Overload
Interventions
SP-420Drug
This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse eventsTime frame: 28 Days
- Completion at original doseTime frame: 28 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mays Cancer Center, UT Health San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.